The DOI matches its Crossref record; 92 of the 92 references it cites were found in a registry or an index.
Nanopharmaceuticals (part 1): products on the market
Open accessAbstract
In 2000, the National Institute of Health launched the National Nanotechnology Initiative to support, coordinate, and advance research and development of nanoscale projects. The impact of this new program on health-science related research and development became quickly visible. Broad governmental financial support advanced the start of new, and the deepening of already existing, interdisciplinary research. The anticipated merger of nanoscience with medicine quickly instigated the conceptualization of nanomedicine. The adoption of nanoscience terminology by pharmaceutical scientists resulted in the advent of nanopharmaceuticals. The term "nano" became tantamount to "cutting-edge" and was quickly embraced by the pharmaceutical science community. Colloidal drug delivery systems reemerged as nanodrug delivery systems; colloidal gold became a suspension of nano gold particles. In this review, we first review nanoscience related definitions applied to pharmaceuticals, we then discuss all 43 currently approved drug formulations which are publicized as nanopharmaceuticals, and finally we analyze clinical aspects of selected drug formulations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review
Maeda, H., Wu, J., Sawa, T., Matsumura, Y., & Hori, K. (2000) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00248-5 · Cited by 6,565
Doxil® — The first FDA-approved nano-drug: Lessons learned
Barenholz, Y. (. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.03.020 · Cited by 4,792
Diffusion of univalent ions across the lamellae of swollen phospholipids
Bangham, A. D., Standish, M. M., & Watkins, J. C. (1965) · Journal of Molecular Biology · doi:10.1016/s0022-2836(65)80093-6 · Cited by 4,664
Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001282 · Cited by 2,837
Walsh, T. J., Anaissie, E. J., Denning, D. W., Herbrecht, R., Kontoyiannis, D. P., Marr, K. A., Morrison, V. A., Segal, B. H., Steinbach, W. J., Stevens, D. A., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/525258 · Cited by 2,706
Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns
Bachmann, M. F., & Jennings, G. T. (2010) · Nature Reviews Immunology · doi:10.1038/nri2868 · Cited by 2,106
Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes
Klibanov, A. L., Maruyama, K., Torchilin, V. P., & Huang, L. (1990) · FEBS Letters · doi:10.1016/0014-5793(90)81016-h · Cited by 2,027
Rooijen, N. V., & Sanders, A. (1994) · Journal of Immunological Methods · doi:10.1016/0022-1759(94)90012-4 · Cited by 1,779
Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size.
Yuan, F., Dellian, M., Fukumura, D., Leunig, M., Berk, D. A., Torchilin, V. P., & Jain, R. K. (1995) · PubMed · Cited by 1,711
Rosenberg, S. A., Aebersold, P., Cornetta, K., Kasid, A., Morgan, R. A., Moen, R., Karson, E. M., Lotze, M. T., Yang, J. C., Topalian, S. L., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199008303230904 · Cited by 1,318
Liposomal Amphotericin B for Empirical Therapy in Patients with Persistent Fever and Neutropenia
Walsh, T. J., Finberg, R. W., Arndt, C., Hiemenz, J., Schwartz, C., Bodensteiner, D., Pappas, P., Seibel, N., Greenberg, R. N., Dummer, S., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903113401004 · Cited by 1,205
Desai, N., Trieu, V., Yao, Z., Louie, L., Ci, S., Yang, A., Tao, C., De, T., Beals, B., Dykes, D., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1634 · Cited by 1,175
The big picture on nanomedicine: the state of investigational and approved nanomedicine products
Etheridge, M. L., Campbell, S. A., Erdman, A. G., Haynes, C. L., Wolf, S. M., & McCullough, J. (2013) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2012.05.013 · Cited by 1,088
Sterically stabilized liposomes
Woodle, M. C., & Lasic, D. D. (1992) · Biochimica et Biophysica Acta (BBA) - Reviews on Biomembranes · doi:10.1016/0304-4157(92)90038-c · Cited by 954
Nanocrystal technology, drug delivery and clinical applications
Müller, R., & Junghanns (2008) · International Journal of Nanomedicine · doi:10.2147/ijn.s595 · Cited by 953
Polymeric Micelles in Anticancer Therapy: Targeting, Imaging and Triggered Release
Oerlemans, C., Bult, W., Bos, M., Storm, G., Nijsen, J. F. W., & Hennink, W. E. (2010) · Pharmaceutical Research · doi:10.1007/s11095-010-0233-4 · Cited by 947
Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline
Berglund, L., Brunzell, J. D., Goldberg, A. C., Goldberg, I. J., Sacks, F., Murad, M. H., & Stalenhoef, A. F. H. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-3213 · Cited by 887
Impact of albumin on drug delivery — New applications on the horizon
Elsadek, B., & Kratz, F. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.09.069 · Cited by 832
Large unilamellar liposomes with low uptake into the reticuloendothelial system
Allen, T. M., & Chonn, A. (1987) · FEBS Letters · doi:10.1016/0014-5793(87)80506-9 · Cited by 729
The Carrier Potential of Liposomes in Biology and Medicine: (First of Two Parts)
Gregoriadis, G. (1976) · New England Journal of Medicine · doi:10.1056/nejm197609232951305 · Cited by 595
Pharmacokinetics of stealth versus conventional liposomes: effect of dose
Allen, T. M., & Hansen, C. (1991) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(91)90201-i · Cited by 579
Glantz, M., Jaeckle, K. A., Chamberlain, M. C., Phuphanich, S., Recht, L. D., Swinnen, L. J., Maria, B., LaFollette, S., Schumann, G. B., Cole, B. F., et al. (1999) · PubMed · Cited by 529
Colloidal Drug Delivery Systems
Kreuter, J. (2014) · CRC Press eBooks · doi:10.1201/9781498710565 · Cited by 469
Allen, T. M., Hansen, C., & Rutledge, J. (1989) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(89)90078-3 · Cited by 466
Mortality and Costs of Acute Renal Failure Associated with Amphotericin B Therapy
Bates, D. W., Su, L., Yu, D. T., Chertow, G. M., Seger, D. L., Gomes, D. R. J., Dasbach, E. J., & Platt, R. (2001) · Clinical Infectious Diseases · doi:10.1086/319211 · Cited by 451
FDA report: Ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease
Lu, M., Cohen, M. H., Rieves, D., & Pazdur, R. (2010) · American Journal of Hematology · doi:10.1002/ajh.21656 · Cited by 443
Prentice, H. G., Hann, I. M., Herbrecht, R., Aoun, M., Kvaloy, S., Catovsky, D., Pinkerton, C. R., Schey, S. A., Jacobs, F., Oakhill, A., et al. (1997) · British Journal of Haematology · doi:10.1046/j.1365-2141.1997.2473063.x · Cited by 439
Current Status of Gendicine in China: Recombinant Human Ad-p53 Agent for Treatment of Cancers
Peng, Z. (2005) · Human Gene Therapy · doi:10.1089/hum.2005.16.1016 · Cited by 436
Colloidal drug delivery systems
Duncan-Hewitt, W. C. (1995) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/0927-7765(95)90010-1 · Cited by 419
Safety considerations with fibrate therapy
Davidson, M. H., Armani, A., McKenney, J. M., & Jacobson, T. A. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.11.016 · Cited by 408
The action of steroids and streptolysin S on the permeability of phospholipid structures to cations
Bangham, A. D., Standish, M. M., & Weissmann, G. (1965) · Journal of Molecular Biology · doi:10.1016/s0022-2836(65)80094-8 · Cited by 407
Lipid Formulations of Amphotericin B: Recent Progress and Future Directions
Hiemenz, J. W., & Walsh, T. J. (1996) · Clinical Infectious Diseases · doi:10.1093/clinids/22.supplement_2.s133 · Cited by 404
Northfelt, D. W., Martin, F. J., Working, P., Volberding, P. A., Russell, J., Newman, M., Amantea, M. A., & Kaplan, L. D. (1996) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1996.tb04152.x · Cited by 378
Wingard, J. R., Kubilis, P., Lee, L., Yee, G., White, M., Louise, W., Bowden, R., Anaissie, E., Hiemenz, J., & Lister, J. (1999) · Clinical Infectious Diseases · doi:10.1086/313498 · Cited by 368
Nanoparticles--a new colloidal drug delivery system.
Marty, J. J., Oppenheim, R. C., & Speiser, P. P. (1978) · PubMed · Cited by 337
Bowden, R., Chandrasekar, P., White, M. H., Li, X., Pietrelli, L., Gurwith, M., van Burik, J., Laverdiere, M., Safrin, S., & Wingard, J. R. (2002) · Clinical Infectious Diseases · doi:10.1086/341401 · Cited by 335
The Carrier Potential of Liposomes in Biology and Medicine: (Second of Two Parts)
Gregoriadis, G. (1976) · New England Journal of Medicine · doi:10.1056/nejm197609302951406 · Cited by 321
Leenders, A. C. A. P., Daenen, S., Jansen, R. L. H., Hop, W. C. J., Lowenberg, B., Wijermans, P. W., Cornelissen, J., Herbrecht, R., Lelie, H. V. D., Hoogsteden, H. C., et al. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00944.x · Cited by 319
White, M. H., Bowden, R. A., Sandler, E. S., Graham, M. L., Noskin, G. A., Wingard, J. R., Goldman, M., van Burik, J., McCabe, A., Lin, J., et al. (1998) · Clinical Infectious Diseases · doi:10.1086/514672 · Cited by 303
Eleven years of Inflexal® V—a virosomal adjuvanted influenza vaccine
Herzog, C., Hartmann, K., Künzi, V., Kürsteiner, O., Mischler, R., Lazar, H., & Glück, R. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.05.029 · Cited by 292
Leenders, A. C. A. P., Reiss, P., Portegies, P., Clezy, K., Hop, W. C. J., Hoy, J., Borleffs, J. C. C., Allworth, T., Kauffmann, R. H., Jones, P., et al. (1997) · AIDS · doi:10.1097/00002030-199712000-00010 · Cited by 289
Greish, K., Fang, J., Inutsuka, T., Nagamitsu, A., & Maeda, H. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342130-00002 · Cited by 278
Davis, F. F. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00021-2 · Cited by 278
Liposomal and Lipid Formulations of Amphotericin B: Clinical Pharmacokinetics
Janknegt, R., de Marie, S., Bakker-Woudenberg, I. A. J. M., & Crommelin, D. J. A. (1992) · Clinical Pharmacokinetics · doi:10.2165/00003088-199223040-00004 · Cited by 274
Chertow, G. M., Burke, S. K., Lazarus, J. M., Stenzel, K. H., Wombolt, D. G., Goldberg, D., Bonventre, J. V., & Slatopolsky, E. (1997) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(97)90009-3 · Cited by 244
Nanomedicine in Action: An Overview of Cancer Nanomedicine on the Market and in Clinical Trials
Wang, R., Billone, P. S., & Mullett, W. M. (2013) · Journal of Nanomaterials · doi:10.1155/2013/629681 · Cited by 236
Lodhia, J., Mandarano, G., Ferris, N., Eu, P., & Cowell, S. (2010) · Biomedical Imaging and Intervention Journal · doi:10.2349/biij.6.2.e12 · Cited by 212
Cation Permeability of Phospholipid Model Membranes: Effect of Narcotics
Bangham, A. D., Standish, M. M., & Miller, N. G. A. (1965) · Nature · doi:10.1038/2081295a0 · Cited by 210
Nanopharmacy: Inorganic nanoscale devices as vectors and active compounds
Rivera Gil, P., Hühn, D., del Mercato, L. L., Sasse, D., & Parak, W. J. (2010) · Pharmacological Research · doi:10.1016/j.phrs.2010.01.009 · Cited by 202
A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations
Barrett, J. P., Vardulaki, K. A., Conlon, C., Cooke, J., Daza-Ramirez, P., Evans, E. G. V., Hawkey, P. M., Herbrecht, R., Marks, D. I., Moraleda, J. M., et al. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)80125-x · Cited by 190
Inflexal®V a trivalent virosome subunit influenza vaccine: production
Mischler, R., & Metcalfe, I. C. (2002) · Vaccine · doi:10.1016/s0264-410x(02)00512-1 · Cited by 183
Eligard: leuprolide acetate in a novel sustained-release delivery system
Sartor, O. (2003) · Urology · doi:10.1016/s0090-4295(02)02396-8 · Cited by 183
Myocet (liposome-encapsulated doxorubicin citrate): a new approach in breast cancer therapy
Batist, G., Barton, J., Chaikin, P., Swenson, C., & Welles, L. (2002) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.3.12.1739 · Cited by 179
Use of anionic liposomes for the reduction of chronic doxorubicin-induced cardiotoxicity.
Forssen, E. A., & Tökés, Z. A. (1981) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.78.3.1873 · Cited by 171
Clinical use of liposomal and lipid-complexed amphotericin B
de Marie, S., Janknegt, R., & Bakker‐Woudenberg, I. A. J. M. (1994) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/33.5.907 · Cited by 133
Gendicine: The First Commercial Gene Therapy Product; Chinese Translation of Editorial
Wilson, J. M. (2005) · Human Gene Therapy · doi:10.1089/hum.2005.16.1014 · Cited by 130
Mifamurtide: A Review of its Use in the Treatment of Osteosarcoma
Frampton, J. E. (2010) · Pediatric Drugs · doi:10.2165/11204910-000000000-00000 · Cited by 128
Mechanism of the selective toxicity of amphotericin B incorporated into liposomes.
Juliano, R. L., Grant, C. W. M., Barber, K. R., & Kalp, M. A. (1987) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)10311-8 · Cited by 118
Nanodrug Delivery Systems: A Promising Technology for Detection, Diagnosis, and Treatment of Cancer
Babu, A., Templeton, A. K., Munshi, A., & Ramesh, R. (2014) · AAPS PharmSciTech · doi:10.1208/s12249-014-0089-8 · Cited by 116
Forssen, E. A., Malé-Brune, R., Adler‐Moore, J., Lee, M. J., Schmidt, P. G., Krasieva, T. B., Shimizu, S., & Tromberg, B. J. (1996) · PubMed · Cited by 103
Insertion of a New Gene of Viral Origin into Bone Marrow Cells of Mice
Mercola, K. E., Stang, H. D., Browne, J. K., et al. (1980) · Science · doi:10.1126/science.6246577 · Cited by 99
Adenosine Deaminase Deficiency
Hirschhorn, R. (2012) · Springer eBooks · doi:10.1007/springerreference_109091 · Cited by 94
A Review of Currently Available Fenofibrate and Fenofibric Acid Formulations
Ling (2013) · Cardiology Research · doi:10.4021/cr270w · Cited by 90
Liver Imaging With Ferumoxides (Feridex??)
Clémеnt, O., Siauve, N., nod, C.-A. C., & Frija, G. G. (1998) · Topics in Magnetic Resonance Imaging · doi:10.1097/00002142-199806000-00003 · Cited by 87
Clinical and Economic Outcomes of Conventional Amphotericin B–Associated Nephrotoxicity
Harbarth, S., Burke, J. P., Lloyd, J. F., Evans, R. S., Pestotnik, S. L., & Samore, M. H. (2002) · Clinical Infectious Diseases · doi:10.1086/344468 · Cited by 86
Phase I and pharmacologie study of liposomal daunorubicin (DaunoXome)
Guaglianone, P. P., Chan, K. K., Delaflor–Weiss, E., Hanisch, R., Jeffers, S., Sharma, D., & Muggia, F. M. (1994) · Investigational New Drugs · doi:10.1007/bf00874439 · Cited by 81
Rexin-G, a targeted genetic medicine for cancer
Gordon, E. M., & Hall, F. L. (2010) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2010.481666 · Cited by 79
Prince, M. R., Zhang, H. L., Chabra, S. G., Jacobs, P. M., & Wang, Y. (2003) · Journal of X-Ray Science and Technology · doi:10.3233/xst-2003-00092 · Cited by 73
Absence of a food effect with a 145 mg nanoparticle fenofibrate tablet formulation
Sauron, R. É., Wilkins, M. R., Jessent, V., Dubois, A., Maillot, C., & Weil, A. (2006) · International Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cpp44064 · Cited by 72
Lipid-based formulations of amphotericin B
Veerareddy, P. R., & Vobalaboina, V. (2004) · Drugs of today · doi:10.1358/dot.2004.40.2.799425 · Cited by 68
Ichikawa, K., Takeuchi, Y., Yonezawa, S., Hikita, T., Kurohane, K., Namba, Y., & Oku, N. (2003) · Cancer Letters · doi:10.1016/j.canlet.2003.10.001 · Cited by 65
Kim, S., Kim, D. J., Geyer, M. A., & Howell, S. B. (1987) · PubMed · Cited by 62
Guivarc'h, P. H., Vachon, M. E., & FORDYCE, D. (2004) · Clinical Therapeutics · doi:10.1016/j.clinthera.2004.09.015 · Cited by 62
Interleukin‐2 Fusion Toxin: Targeted Therapy for Cutaneous T Cell Lymphoma
Foss, F. M. (2001) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2001.tb03720.x · Cited by 61
Foote, M. (2007) · Biotechnology annual review · doi:10.1016/s1387-2656(07)13012-x · Cited by 53
The Potentials of Inserting New Genetic Information
Mercola, K. E., & Cline, M. J. (1980) · New England Journal of Medicine · doi:10.1056/nejm198011273032211 · Cited by 46
Extended‐Release Epidural Morphine (DepoDur™): An Old Drug with a New Profile
Alam, M., & Hartrick, C. T. (2005) · Pain Practice · doi:10.1111/j.1533-2500.2005.00048.x · Cited by 45
Avoidance of Generic Competition by Abbott Laboratories' Fenofibrate Franchise
Downing, N. S., Ross, J. S., Jackevicius, C. A., & Krumholz, H. M. (2012) · Archives of Internal Medicine · doi:10.1001/archinternmed.2012.187 · Cited by 38
Mehta, J. (1997) · Leukemia Research · doi:10.1016/s0145-2126(96)00075-6 · Cited by 37
Cline, M. J. (1985) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(85)90017-8 · Cited by 32
Frishman, W. H. (2007) · Yearbook of Medicine · doi:10.1016/s0084-3873(08)70201-3 · Cited by 28
Lamy, M. T., Ferreira, V. F. N., & Schreier, S. (1989) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(89)90030-8 · Cited by 27
Membrane‐to‐Membrane Transfer of Lipophilic Drugs Used against Cancer or Infectious Diseasea
Juliano, R. L., Daoud, S. S., Krause, H.-J., et al. (1987) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1987.tb45794.x · Cited by 19
Ishii, H. (2003) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyg106 · Cited by 19
Maciejewski, S. R., & Hilleman, D. E. (2008) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.28.5.570 · Cited by 12
Gruß, P., & Khoury, G. (1982) · Current topics in microbiology and immunology · doi:10.1007/978-3-642-68315-2_10 · Cited by 7
Erlinda, M., & Frederick, L. (2011) · InTech eBooks · doi:10.5772/21120 · Cited by 5
Davidson, M. H., & Jones, P. H. (2008) · Clinical Drug Investigation · doi:10.2165/00044011-200828100-00002 · Cited by 5
Cited by
PEGylation as a strategy for improving nanoparticle-based drug and gene delivery
Suk, J. S., Xu, Q., Kim, N., Hanes, J., & Ensign, L. M. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.09.012 · Cited by 4,523
Tenchov, R., Bird, R., Curtze, A. E., & Zhou, Q. (2021) · ACS Nano · doi:10.1021/acsnano.1c04996 · Cited by 2,221
The History of Nanoscience and Nanotechnology: From Chemical–Physical Applications to Nanomedicine
Bayda, S., Adeel, M., Tuccinardi, T., Cordani, M., & Rizzolio, F. (2019) · Molecules · doi:10.3390/molecules25010112 · Cited by 2,016
Therapeutic Nanoparticles and Their Targeted Delivery Applications
Yetisgin, A. A., Cetinel, S., Zuvin, M., Kosar, A., & Kutlu, O. (2020) · Molecules · doi:10.3390/molecules25092193 · Cited by 1,080
Nanopharmaceuticals and Nanomedicines Currently on the Market: Challenges and Opportunities
Farjadian, F., Ghasemi, A., Gohari, O., Roointan, A., Karimi, M., & Hamblin, M. R. (2019) · Nanomedicine · doi:10.2217/nnm-2018-0120 · Cited by 664
Metadata
- Authors
- Weissig, V., Pettinger, T., & Murdock, N.
- Venue
- International Journal of Nanomedicine
- Publisher
- Informa UK Limited
- Published
- 2014-09
- Volume
- 9
- Pages
- 4357
- ISSN
- 1176-9114 (ISSN-L)
- 1178-2013
- OpenAlex
- W2058865733
- Cited by
- 591
- References
- 92
- FWCI
- 16.44
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.